Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
Jovana Nazor, Milpitas, CA (US); Derek J. Smith, Singapore (SG); Michael A. Crowe, Singapore (SG); Shiwei Song, Singapore (SG); and Steven J. Collier, Concord, MA (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Jul. 19, 2021, as Appl. No. 17/379,843.
Application 15/180,355 is a division of application No. 14/828,839, filed on Aug. 18, 2015, granted, now 9,388,395, issued on Jul. 12, 2016.
Application 14/828,839 is a division of application No. 14/386,082, granted, now 9,139,821, issued on Sep. 22, 2015, previously published as PCT/US2013/033456, filed on Mar. 22, 2013.
Application 17/379,843 is a continuation of application No. 16/707,724, filed on Dec. 9, 2019, granted, now 11,098,291.
Application 16/707,724 is a continuation of application No. 15/623,698, filed on Jun. 15, 2017, granted, now 10,544,402, issued on Jan. 28, 2020.
Application 15/623,698 is a continuation of application No. 15/180,355, filed on Jun. 13, 2016, granted, now 9,708,588, issued on Jul. 18, 2017.
Claims priority of provisional application 61/614,666, filed on Mar. 23, 2012.
Prior Publication US 2021/0348139 A1, Nov. 11, 2021
1. An engineered polypeptide having transaminase activity, comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 4, and a residue difference X284A/G as compared to SEQ ID NO: 4.